Results 71 to 80 of about 416,036 (340)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation

Medicina, 2022
Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed.
Hyemi Ko, Myungsun Lee, Eunyoung Cha, Jiyoung Sul, Junbeom Park, Jinsun Lee   +5 more
doaj   +1 more source

The Molecular Perspective: Cisplatin [PDF]

Stem Cells, 2006
Learning Objective After completing this course, the reader will be able to: Describe the structure and action of cisplatin. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com
openaire   +4 more sources

Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway. [PDF]

, 2015
Tumor recurrence remains an obstacle after liver surgery, especially in living donor liver transplantation (LDLT) for patients with hepatocellular carcinoma (HCC).
Geng, Wei, Li, Chang-Xian, Ling, Chang-Chun, Liu, Xiao-Bing, Lo, Chung-Mau, Ma, Yuen-Yuen, Man, Kwan, Ng, Kevin TP, Qi, Xiang, Zhai, Yuan   +9 more
core   +1 more source

Cucurbit[n]uril binding of platinum anticancer complexes [PDF]

, 2005
The encapsulation of cisplatin by cucurbit[7]uril (Q[7]) and multinuclear platinum complexes linked via a 4,4′-dipyrazolylmethane (dpzm) ligand by Q[7] and cucurbit[8]uril (Q[8]) has been studied by NMR spectroscopy and molecular modelling.
Anthony I. Day, Baird, Bancroft, Battle, Blanch, Blasi, Boulikas, Calvert, Clarke, Colella, Collins, Damian P. Buck, Day, Farrell, Farrell, Farrell, Farrell, Farrell, Fu, Hartmann, Hegmans, J. Grant Collins, Jansen, Jeon, Jeon, Jodrell, Kelland, Kelland, Kim, Kim, Lorenzo, Manzotti, Marquez, Mock, Mock, Nial J. Wheate, Ong, Pavankumar, Perego, Perego, Perego, Piccart, Pratesi, Riccardi, Roberts, Roberts, Scagilotti, Servidei, Sessa, Sharp, Villa, Wheate, Wheate, Wheate, Wheate, Wheate, Wheate, Wong, Zhang   +58 more
core   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

Molecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker, Elysia Sarsam, Stuart J. Conway, Ester M. Hammond   +3 more
wiley   +1 more source

Quantification of Cisplatin Encapsulated in Nanomedicine: An Overview

Biosensors
Cisplatin, which kills cancer cells mainly through DNA crosslinking, has been widely used as a first-line chemotherapeutic agent although it also causes severe side effects.
Ziwen Zhang, Jiayu Chen, Tao Wen, Hong Deng, Yiyi Zhang, Hua Guo, Hui Chang, Haiyan Xu, Weiqi Zhang   +8 more
doaj   +1 more source

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

FEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash, Campbell W. Gourlay, Ina Oehme, Michelle D. Garrett, Jindrich Cinatl Jr, Mark N. Wass, Martin Michaelis   +6 more
wiley   +1 more source

Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process

Pharmaceutics
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability.
Sudhir Kumar Sharma, Loganathan Palanikumar, Renu Pasricha, Thirumurugan Prakasam, Mazin Magzoub, Ramesh Jagannathan   +5 more
doaj   +1 more source

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells

Taiwanese Journal of Obstetrics & Gynecology, 2011
Objective: There is a need to develop alternative therapeutic strategies to overcome cisplatin-associated resistance in patients with ovarian cancer. Histone deacetylation (HDAC) associated with inactivation of genes has been implicated in the epigenetic
Yen-Ying Ma, Hao Lin, Jau-Sung Moh, Kuang-Den Chen, I-Wen Wang, Yu-Che Ou, Ying-Shu You, Chia-Chi Lung   +7 more
doaj   +1 more source

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma [PDF]

, 2003
BACKGROUND: We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used
A du Bois, A Villa, Alan Lamont, AN Gordon, Andrew C Hindley, B Lund, Bernard R Higgins, Christian M Kurbacher, CM Kurbacher, CM Kurbacher, DD Von Hoff, DD Von Hoff, DL Clarke-Pearson, DS Ettinger, EM Hunter, Federica Di Nicolantonio, G Blackledge, G Konecny, GJ Rustin, GJ Rustin, IA Cree, IA Cree, IA Cree, Ian A Cree, J Kaern, JS Berek, JT Thigpen, KA Donovan, Louise A Knight, M Breidenbach, M Breidenbach, M Gore, M Harries, M Markman, M Markman, M Markman, M Markman, Martin Gore, ME Gore, ME Gore, ME van der Burg, MH Neale, Michael H Neale, MJ Piccart, ML Hensley, N Myatt, OM Grecu, P Hanjani, P Therasse, Pauline A Whitehouse, PE Andreotti, PG Rose, RD Petty, Richard Osborne, Robert T. Greenlee, Sanjay Sharma, Stuart J Mercer, T Meyer, U Kurbacher CM Stier, WP McGuire   +59 more
core   +4 more sources